Abliva AB (publ) (NEVPF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 27.86 Million SEK | -93.77% |
| 2022 | 84.93 Million USD | 750.64% |
| 2021 | 9.98 Million USD | 177.88% |
| 2020 | 3.59 Million USD | -31.06% |
| 2019 | 5.21 Million USD | 16.7% |
| 2018 | 4.46 Million SEK | 30.94% |
| 2017 | 3.41 Million SEK | 158.19% |
| 2016 | 1.32 Million SEK | -9.9% |
| 2015 | 1.46 Million SEK | -97.16% |
| 2014 | 51.62 Million SEK | 86.51% |
| 2013 | 27.68 Million SEK | 67.77% |
| 2012 | 16.49 Million SEK | 6.96% |
| 2011 | 15.42 Million SEK | 98.39% |
| 2010 | 7.77 Million SEK | 29.57% |
| 2009 | 6 Million SEK | 139.3% |
| 2008 | 2.5 Million SEK | 104.34% |
| 2007 | 1.22 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.34 Million USD | 38.95% |
| 2024 Q1 | 1.73 Million USD | 11.22% |
| 2023 FY | 5.29 Million USD | -93.77% |
| 2023 Q2 | 2.14 Million USD | 35.34% |
| 2023 Q3 | 2.13 Million USD | -0.56% |
| 2023 Q4 | 1.64 Million USD | -23.09% |
| 2023 Q1 | 1.58 Million USD | -10.74% |
| 2022 Q2 | 1.01 Million SEK | -54.18% |
| 2022 Q3 | 1.74 Million USD | 72.0% |
| 2022 Q4 | 1.77 Million USD | 2.21% |
| 2022 FY | 84.93 Million USD | 750.64% |
| 2022 Q1 | 2.2 Million SEK | -93.96% |
| 2021 Q3 | 2.65 Million SEK | 9.61% |
| 2021 Q4 | 36.58 Million SEK | 1278.3% |
| 2021 Q1 | 2.36 Million SEK | -82.35% |
| 2021 Q2 | 2.42 Million SEK | 2.54% |
| 2021 FY | 9.98 Million USD | 177.88% |
| 2020 Q3 | 10.07 Million SEK | -50.64% |
| 2020 Q4 | 13.38 Million SEK | 32.9% |
| 2020 FY | 3.59 Million USD | -31.06% |
| 2020 Q1 | 16.53 Million SEK | -38.64% |
| 2020 Q2 | 20.4 Million SEK | 23.37% |
| 2019 Q2 | 20.84 Million SEK | 50.91% |
| 2019 FY | 5.21 Million USD | 16.7% |
| 2019 Q1 | 13.81 Million SEK | -28.62% |
| 2019 Q3 | 15.28 Million SEK | -26.65% |
| 2019 Q4 | 26.94 Million SEK | 76.29% |
| 2018 Q1 | 12.99 Million SEK | -13.95% |
| 2018 Q2 | 25.16 Million SEK | 93.66% |
| 2018 Q3 | 15.07 Million SEK | -40.09% |
| 2018 Q4 | 19.34 Million SEK | 28.33% |
| 2018 FY | 4.46 Million SEK | 30.94% |
| 2017 Q4 | 15.1 Million SEK | 18.04% |
| 2017 Q3 | 12.79 Million SEK | -42.24% |
| 2017 Q2 | 22.14 Million SEK | 4.16% |
| 2017 Q1 | 21.26 Million SEK | 414.22% |
| 2017 FY | 3.41 Million SEK | 158.19% |
| 2016 Q2 | 12.11 Million SEK | 10.8% |
| 2016 Q1 | 10.93 Million SEK | 151.28% |
| 2016 Q3 | 34.18 Million SEK | 182.11% |
| 2016 FY | 1.32 Million SEK | -9.9% |
| 2016 Q4 | -6.76 Million SEK | -119.79% |
| 2015 Q1 | 14.71 Million SEK | -15.66% |
| 2015 Q3 | 54.05 Million SEK | 203.24% |
| 2015 Q4 | -21.33 Million SEK | -139.46% |
| 2015 Q2 | 17.82 Million SEK | 21.11% |
| 2015 FY | 1.46 Million SEK | -97.16% |
| 2014 Q4 | 17.45 Million SEK | 58.71% |
| 2014 FY | 51.62 Million SEK | 86.51% |
| 2014 Q1 | 9.86 Million SEK | 6.18% |
| 2014 Q2 | 14.09 Million SEK | 42.96% |
| 2014 Q3 | 10.99 Million SEK | -21.98% |
| 2013 Q1 | 4.86 Million SEK | -9.15% |
| 2013 FY | 27.68 Million SEK | 67.77% |
| 2013 Q4 | 9.28 Million SEK | 39.2% |
| 2013 Q3 | 6.67 Million SEK | -2.77% |
| 2013 Q2 | 6.86 Million SEK | 41.09% |
| 2012 Q2 | 4.13 Million SEK | 44.61% |
| 2012 Q1 | 2.85 Million SEK | -11.39% |
| 2012 FY | 16.49 Million SEK | 6.96% |
| 2012 Q4 | 5.35 Million SEK | 28.68% |
| 2012 Q3 | 4.16 Million SEK | 0.73% |
| 2011 Q4 | 3.22 Million SEK | 31.88% |
| 2011 FY | 15.42 Million SEK | 98.39% |
| 2011 Q2 | 3.16 Million SEK | 112.79% |
| 2011 Q1 | 1.48 Million SEK | -37.32% |
| 2011 Q3 | 2.44 Million SEK | -22.71% |
| 2010 Q1 | 921.59 Thousand SEK | -56.19% |
| 2010 FY | 7.77 Million SEK | 29.57% |
| 2010 Q3 | 3.2 Million SEK | 150.77% |
| 2010 Q2 | 1.27 Million SEK | 38.67% |
| 2010 Q4 | 2.37 Million SEK | -26.02% |
| 2009 FY | 6 Million SEK | 139.3% |
| 2009 Q2 | 1.33 Million SEK | 29.03% |
| 2009 Q1 | 1.03 Million SEK | 0.0% |
| 2009 Q3 | 1.52 Million SEK | 14.7% |
| 2009 Q4 | 2.1 Million SEK | 37.54% |
| 2008 FY | 2.5 Million SEK | 104.34% |
| 2007 FY | 1.22 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | -663.304% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1977.157% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -960.543% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 5.708% |
| GB Sciences, Inc. | 1.42 Million USD | -1861.691% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -718.39% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -12561.874% |
| Skye Bioscience, Inc. | 13.54 Million USD | -105.69% |
| Zenith Capital Corp. | 8.94 Million USD | -211.596% |
| Agentix Corp. | 1.37 Million USD | -1931.411% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -452.673% |
| Biomind Labs Inc. | 994.18 Thousand USD | -2702.907% |
| ContraFect Corporation | 56.88 Million USD | 51.017% |
| CSL Limited | 3.44 Billion USD | 99.192% |
| CytoDyn Inc. | 18.05 Million USD | -54.314% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1394.66% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -7053.088% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 51.487% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -6606.958% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1755.384% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -2917.401% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 25.203% |
| SQZ Biotechnologies Company | 85.61 Million USD | 67.453% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1260.176% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 67.891% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -855.547% |
| Mesoblast Limited | 5.9 Million USD | -372.145% |
| Marizyme, Inc. | 19.23 Million USD | -44.835% |
| Genus plc | 147.7 Million USD | 81.133% |
| Pharming Group N.V. | 225.49 Million USD | 87.642% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -234.165% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1784.427% |
| IMV Inc. | 37.7 Million USD | 26.103% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -898.654% |
| MultiCell Technologies, Inc. | 567.42 USD | -4910900.67% |
| ONE Bio Corp. | 6.44 Million USD | -332.441% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 67.577% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -12.749% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1483.585% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -314.795% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 111564.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -74.051% |
| Alpha Cognition Inc. | 9.7 Million USD | -187.113% |
| Enzolytics Inc. | 2.17 Million USD | -1178.546% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.183% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -2569.157% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1058.701% |
| Genscript Biotech Corporation | 825.34 Million USD | 96.624% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -466.622% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -10547.013% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1034.925% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -16147.544% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1350.67% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -217.408% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -532.072% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -643.804% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1313.059% |
| EV Biologics, Inc. | 531.96 Thousand USD | -5138.344% |
| Q BioMed Inc. | 3.43 Million USD | -710.853% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -156.428% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 71.946% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -21.289% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1418.504% |
| HST Global, Inc. | 140.9 Thousand USD | -19676.164% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1986.667% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -2377.176% |
| Halberd Corporation | 74.84 Thousand USD | -37133.104% |
| Resverlogix Corp. | 12.71 Million USD | -119.21% |
| Cell Source, Inc. | 4.32 Million USD | -544.249% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1664.391% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -281.19% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -159856.374% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -1029.66% |
| Kadimastem Ltd | 2.41 Million USD | -1056.212% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -557.463% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -15254.437% |
| LadRx Corporation | 3.81 Million USD | -631.047% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -2917.401% |
| Affymax, Inc. | 39.38 Million USD | 29.249% |
| Itoco Inc. | 919.14 Thousand USD | -2931.737% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -2390.259% |
| Mobile Lads Corp. | 554.54 Thousand USD | -4925.011% |
| International Stem Cell Corporation | 5.27 Million USD | -428.666% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -629.448% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -110615.563% |
| Qrons Inc. | 643.67 Thousand USD | -4229.19% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1862.682% |
| SYBLEU INC | 160.87 Thousand USD | -17221.415% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1149.664% |
| Rebus Holdings, Inc. | 664 Thousand USD | -4096.687% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1434.201% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -52834.919% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -136880.78% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 23.162% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1622.25% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -3686.99% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -795.725% |
| Neutra Corp. | 243.82 Thousand USD | -11328.876% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -59.627% |
| PureTech Health plc | 144.59 Million USD | 80.729% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -35.999% |
| IXICO plc | 4.7 Million USD | -492.012% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -216.767% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 76.334% |
| CSL Limited | 3.89 Billion USD | 99.284% |
| Cellectis S.A. | 97.32 Million USD | 71.367% |